Pharma group Proteome Sciences has had a strong morning on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer's disease.
A study of 1,000 patients has shown three distinct "biomarkers" in people's blood which can discriminate between mild "cognitive impairment" (a syndrome often preceding Alzheimer's), Alzheimer's itself and control groups who do not have the condition.
Proteome Sciences is filing patents for the "panels" in the blood that contain the biomarkers.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
It is estimated that 60% of people with Alzheimer's disease have not been properly diagnosed and therefore are not being given the correct drugs and care.
The capability to distinguish between different levels of the disease will enable drug developers to improve patient care and people with mild symptoms are likely to benefit the most from new disease-modifying drugs.
The key is that Proteome may be able to develop a simple blood test to determine progression of Alzheimer's as opposed to the current diagnostic methods of invasive lumbar punctures or expensive MRI scans.
Presenting the data at a conference in Melbourne, Australia, Professor Simon Lovestone, who has worked with Proteome for the National Institute for Health Research said: "As new treatments for Alzheimer's disease are being developed, there is an increasing need for accurate and accessible markers of disease severity and progression. We will move quickly to support the development of clinical tests based on these biomarker panels."
Shares in Proteome had risen 8.85% by 11:08.
BS
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
-
What does Rachel Reeves’s plan for growth mean for UK investors?Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
